Suppr超能文献

大剂量皮质类固醇对感染性休克患者的影响。一项前瞻性对照研究。

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study.

作者信息

Sprung C L, Caralis P V, Marcial E H, Pierce M, Gelbard M A, Long W M, Duncan R C, Tendler M D, Karpf M

出版信息

N Engl J Med. 1984 Nov 1;311(18):1137-43. doi: 10.1056/NEJM198411013111801.

Abstract

To determine whether corticosteroids are efficacious in severe septic shock, we conducted a prospective study of 59 patients randomly assigned to a methylprednisolone, dexamethasone, or control group. Patients were treated 17.5 +/- 5.4 hours (mean +/- S.E.M.) after the onset of shock, and 55 patients required vasopressor agents. Early in the hospital course, reversal of shock was more likely in patients who received corticosteroids than in those who did not. Four (19 per cent) of 21 methylprednisolone-treated, 7 (32 per cent) of 22 dexamethasone-treated, and none of 16 control patients had reversal of shock 24 hours after drug administration (corticosteroid groups vs. control group, P less than 0.05). Patients treated with corticosteroids within four hours after the onset of shock had a higher incidence of shock reversal (P less than 0.05). At 133 hours after drug administration, 17 (40 per cent) of 43 corticosteroid-treated patients had died, and 11 (69 per cent) of 16 control patients had died (P less than 0.05). However, these differences in reversal of shock and survival disappeared later in the course. Overall, 16 (76 per cent) of 21 patients receiving methylprednisolone, 17 (77 per cent) of 22 patients receiving dexamethasone, and 11 (69 per cent) of 16 controls in the hospital died. We conclude that corticosteroids do not improve the overall survival of patients with severe, late septic shock but may be helpful early in the course and in certain subgroups of patients.

摘要

为了确定皮质类固醇对严重感染性休克是否有效,我们对59例患者进行了一项前瞻性研究,这些患者被随机分配至甲泼尼龙组、地塞米松组或对照组。患者在休克发作后17.5±5.4小时(均值±标准误)开始接受治疗,其中55例患者需要血管加压药物治疗。在病程早期,接受皮质类固醇治疗的患者比未接受治疗的患者更有可能逆转休克。在用药24小时后,21例接受甲泼尼龙治疗的患者中有4例(19%)、22例接受地塞米松治疗的患者中有7例(32%)逆转了休克,而16例对照组患者中无一例逆转休克(皮质类固醇组与对照组相比,P<0.05)。在休克发作后4小时内接受皮质类固醇治疗的患者休克逆转发生率更高(P<0.05)。在用药133小时后,43例接受皮质类固醇治疗的患者中有17例(40%)死亡,16例对照组患者中有11例(69%)死亡(P<0.05)。然而,这些休克逆转和生存方面的差异在病程后期消失。总体而言,住院期间接受甲泼尼龙治疗的21例患者中有16例(76%)、接受地塞米松治疗的22例患者中有17例(77%)以及16例对照组患者中有11例(69%)死亡。我们得出结论,皮质类固醇不能提高严重晚期感染性休克患者的总体生存率,但在病程早期及某些亚组患者中可能有帮助。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验